Quarterly Results

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.

NSE : NABSE : 524663ISIN CODE : INE994B01014Industry : Pharmaceuticals & DrugsHouse : PSU
BSE32.24-0.81 (-2.45 %)
PREV CLOSE ( ) 33.05
OPEN PRICE ( ) 33.49
BID PRICE (QTY) 32.23 (1)
OFFER PRICE (QTY) 32.29 (1)
VOLUME 60080
TODAY'S LOW / HIGH ( )31.90 33.49
52 WK LOW / HIGH ( ) 20.543.89
NSE
This Company is not listed in NSE
Quarters
Select year  
( in Million)
Particulars
Sep 2023
Jun 2023
Dec 2022
Sep 2022
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
NA
NA
NA
264.8
Total Expenditure
46.88
43.13
47.27
289.8
PBIDT (Excl OI)
-46.88
-43.13
-47.27
-25
Other Income
1.64
1.02
1.02
3.2
Operating Profit
-45.24
-42.11
-46.25
-21.80
Interest
20.87
17.21
16.68
17.42
Exceptional Items
NA
NA
NA
NA
PBDT
-66.11
-59.32
-62.93
-39.22
Depreciation
0.34
0.34
0.37
0.36
Profit Before Tax
-66.45
-59.66
-63.3
-39.58
Tax
-17.28
-13.8
-16.45
-8.76
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
-49.17
-45.86
-46.85
-30.82
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
0.00
0.00
0.00
0.00
Net Profit
-49.17
-45.86
-46.85
-30.82
Equity Capital
431.8
431.8
431.8
431.8
Face Value (IN RS)
10
10
10
10
Reserves
Calculated EPS
-1.13
-1.06
-1.08
-0.71
Calculated EPS (Annualised)
-4.55
-4.24
-4.33
-2.85
No of Public Share Holdings
17594000
17594000
17594000
17594000
% of Public Share Holdings
40.75
40.75
40.75
40.75
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
NA
NA
NA
-9.44
PBIDTM%
NA
NA
NA
-8.23
PBDTM%
NA
NA
NA
-14.81
PBTM%
NA
NA
NA
-14.95
PATM%
NA
NA
NA
-11.64
 
Notes
Notes
Notes
Notes

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.